CD8A and neoplasm: This was a redox responsive formulation, which led to the stimulation of pro-inflammatory cytokine production and DC maturation in vivo, as well as the reprogramming of the tumor immune microenvironment by inducing more immunogenic cell death (ICD) (of tumor cells), CD8+ T cells, and activated antigen presentation cells (APCs).